Hayfever vaccine study raises hopes for new allergy treatment as clinical trial is launched
Researchers are developing a new vaccine for hayfever which could be more effective, less invasive for patients and less expensive than vaccines already available to patients within the NHS.
Scientists at Imperial College London and King's College London have carried out a study which showed a significant reduction in skin sensitivity to grass pollen that was associated with an increase in 'blocking antibodies' in the bloodstream. The results are so encouraging that King's has today launched a clinical trial in collaboration with Guy's Hospital, working together as part of King's Health Partners. The trial is funded by the Medical Research Council and National Institute for Health Research via the Efficacy and Mechanism Evaluation programme, and will further investigate the vaccine as a potential new hayfever treatment.
The researchers say the approach defines a completely new concept in treating allergies and in the future could have an impact on treating other conditions such as asthma and food allergies.
Hayfever affects one in four people in the UK. An allergic reaction to grass pollen triggers a blocked or runny nose, sneezing, itchy eyes and in some cases asthma symptoms. For many individuals this can interfere with work or school performance, sleep and social activities. Tablets and sprays may temporarily relieve symptoms, but for severe cases one option is a vaccine to 'switch off' the allergy, called immunotherapy.
The vaccines currently used involve high doses of allergen given by injection underneath the skin (subcutaneously) or sometimes as a daily tablet or drops under the tongue. In most cases this involves large numbers of injections in an NHS allergy clinic or daily tablets/drops taken continuously, which can be inconvenient for patients and expensive for the NHS.
Published today in the Journal of Allergy and Clinical Immunology, this new study shows that a series of low dose allergen injections (less than a 1000th of the usual dose) into a higher layer of the skin (intradermally), rather than subcutaneously, led to a 90 per cent reduction in skin reactivity to grass pollen.
Researchers administered the vaccine intradermally to volunteer hayfever sufferers from Royal Brompton and Harefield NHS Foundation Trust. One group of subjects received six injections of grass pollen extract at two-week intervals over 10 weeks. The participants' allergic responses in the skin were then measured. The initial injection provoked an allergic reaction on the arm visible as a lump around 10 cm in diameter lasting 1-2 days. Over time a dramatic 90 per cent reduction was seen in the size of the lump suggesting that the allergic reaction was gradually being switched off with each injection. The size of the lump did not decrease in another group of subjects who received only two injections separated by 10 weeks.
During the study none of the participants reported unwanted side-effects and the injections did not trigger hayfever symptoms.
The researchers believe that the method of injecting the vaccine intradermally is a major factor in its success, as the skin is a highly active immunological area – more so than underneath the skin where allergy vaccines are traditionally administered.
Dr Stephen Till, Senior Lecturer at King's College London, said: 'The results of our study are hugely exciting. We now want to find out if this process can also switch off grass allergy in the nose and improve hayfever symptoms, so we are today launching the PollenLITE clinical trial to further test our new approach.'
Professor Stephen Durham, Head of Allergy and Clinical Immunology at Imperial College London, said: 'There is great interest in giving immunotherapy by novel alternative routes to improve uptake by the immune system. The results of this study provide an excellent foundation for going on to test the intradermal vaccine route in clinical trials.'
King's College London and Guy's and St Thomas' NHS Foundation Trust, as part of King's Health Partners Academic Health Sciences Centre, are today launching the PollenLITE trial to test this new vaccine. The trial is a collaboration with Imperial College London, which together with King's College London forms the basis of the MRC and Asthma UK Centre in Allergic Mechanisms of Asthma.
The PollenLITE team is looking for 90 hayfever sufferers to take part. Volunteers will receive either seven injections of small quantities of grass pollen into the dermis, or a placebo (dummy) injection in early 2013. In the summer of 2013 study participants will record their symptoms daily and scores will later be compared in the two groups. Small samples of skin and blood at the beginning and end of the study will be taken for experiments into how this new treatment works.
Dr Till at King's concluded: 'Hayfever is one of the most common diseases in the UK and can have a serious impact on people's everyday lives. PollenLITE is a major trial that has the potential to identify a new treatment that is more effective, convenient and cheaper for the NHS than the current alternative.
'Crucially, if this approach proves to be effective it would define a new scientific and clinical principle that could also be applied to other allergic diseases such as asthma and food allergies. This could be a pivotal study in immunological research.'
Journal reference: Journal of Allergy and Clinical Immunology
Provided by King's College London
- Desensitisation approaches effective against hayfever-like allergies Dec 08, 2010 | not rated yet | 0
- Get ready for spring - hay fever worse in spring than summer Dec 21, 2011 | not rated yet | 0
- Grass pollen allergy research tackles hay fever Sep 03, 2012 | not rated yet | 0
- Allergy vaccine is nothing to sneeze at Mar 21, 2011 | not rated yet | 0
- Fight against hay fever and other allergies helped by new immune system discovery Dec 27, 2007 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011 I'd like to open a discussion thread for version 2 of the draft of my book ''Classical and Quantum Mechanics via Lie algebras'', available online at http://lanl.arxiv.org/abs/0810.1019 , and for the...
- More from Physics Forums - Independent Research
More news stories
As the world prepares for what may be the next pandemic strain of influenza virus, in the H7N9 bird flu, a new UC Irvine study reveals that the 2009 H1N1 swine flu pandemic was deadliest for people under the age of 65, while ...
Diseases, Conditions, Syndromes 10 hours ago | not rated yet | 0
The World Health Organization says the Horn of Africa is experiencing an outbreak of polio with cases confirmed in Kenya and Somalia.
Diseases, Conditions, Syndromes 11 hours ago | not rated yet | 0
A man who had contracted the coronavirus has died in Saudi Arabia, raising the death toll in the kingdom from the SARS-like virus to 17, the health ministry announced on its website on Wednesday.
Diseases, Conditions, Syndromes 11 hours ago | not rated yet | 0
A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...
Diseases, Conditions, Syndromes 11 hours ago | not rated yet | 0 |
Patients with underlying heart failure are more likely to experience adverse outcomes from mild hypothyroidism, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & ...
Diseases, Conditions, Syndromes 13 hours ago | not rated yet | 0
Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.
14 hours ago | 4.9 / 5 (7) | 0 |
Existing research shows that bicyclists who wear helmets have an 88 percent lower risk of brain injury, but researchers at Boston Children's Hospital found that simply having bicycle helmet laws in place showed a 20 percent ...
3 hours ago | not rated yet | 0
Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.
14 hours ago | 4.7 / 5 (3) | 0 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
11 hours ago | 5 / 5 (2) | 2 |
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
11 hours ago | 4 / 5 (2) | 0 |
In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe ...
13 hours ago | 5 / 5 (1) | 0 |